HAVCR2 and acute myeloid leukemia: However, TIM-3+ frequencies had no significant differences in CD34+ (12.8% (0.18–64.2%) vs. 9.6% (8.6–11.6%), p = 0.36) and CD34+CD38+ (14.6% (0.10–75.4%) vs. 10.1% (9.0–13.1%), p = 0.32) cells between AML patients and HDs (Figure 1B,C).